Admitted local publications that cite Dupilumab Targeting IL ‐4/ IL ‐13 Pathway Improves RTK ‐ and PD ‐1‐Inhibitor‐Related Cutaneous Adverse Drug Reactions.
No admitted local citation edges point to this work yet.
Cited by — Dupilumab Targeting IL ‐4/ IL ‐13 Pathway Improves RTK ‐ and PD ‐1‐Inhibitor‐Related Cutaneous Adverse Drug Reactions | ResearchHub - ResearchHub
